Ulcerative Colitis Celgene’s Therapy Ozanimod Shows Promising Results in Phase 2 Trial

Ulcerative Colitis Celgene’s Therapy Ozanimod Shows Promising Results in Phase 2 Trial
Celgene Corporation, a biopharmaceutical company focused on the development of innovative therapies for cancer and immune-inflammatory related diseases, recently announced the results of the “maintenance phase” of its Phase 2 clinical trial TOUCHSTONE, assessing the company’s investigational drug Ozanimod in patients with ulcerative colitis. The results were presented at the American College of Gastroenterology (ACG)

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *